SCHEMBL4941264

SCHEMBL4941264

CS(=O)(=O)c1ccc(-c2ccc(C#N)cc2)c(C(=O)O)c1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC6A9 P48067 3/20 0.52
LMNA P02545 1/20 0.50
PTGS2 P35354 2/20 0.49
EIF4E P06730 2/20 0.46
MMP1 P03956 2/20 0.43
MMP2 P08253 2/20 0.43
MMP3 P08254 2/20 0.43
MMP7 P09237 2/20 0.43
MMP9 P14780 2/20 0.43
MMP13 P45452 2/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA9 Q16790 1/20 0.43
HSD17B10 Q99714 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3875822 0.82 LMNA (0.58) SLC6A9LMNAPTGS2HSD17B10
SCHEMBL3875280 0.81 LMNA (0.62) LMNAPTGS2EIF4EHSD17B10SMN1; SMN2
SCHEMBL1812902 0.81 PTGS2 (0.58) SLC6A9LMNAPTGS2
SCHEMBL8259316 0.81 LMNA (0.54) SLC6A9LMNAPTGS2HSD17B10SMN1; SMN2
SCHEMBL23953177 0.80 PTGS2 (0.54) PTGS2CA12CA1CA2CA9
SCHEMBL4942150 0.79 SMN1; SMN2 (0.70) LMNAPTGS2SMN1; SMN2
SCHEMBL21742989 0.78 CYP11B1 (0.57) PTGS2CA12CA1CA2CA9
SCHEMBL3873005 0.78 LMNA (0.54) SLC6A9LMNAPTGS2EIF4EHSD17B10
SCHEMBL3872697 0.76 LMNA (0.51) SLC6A9LMNAPTGS2
SCHEMBL3880622 0.75 LMNA (0.54) SLC6A9LMNAPTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255144-A1 Acylated Piperidines as Glycine Transporter Inhibitors GLAXO GROUP LIMITED 2008-10-16 US disclosed
US-20080255144-A1 Acylated Piperidines as Glycine Transporter Inhibitors GLAXO GROUP LIMITED 2008-10-16 US disclosed
US-20080255144-A1 Acylated Piperidines as Glycine Transporter Inhibitors GLAXO GROUP LIMITED 2008-10-16 US disclosed
EP-1858869-A1 ACYLATED PIPERIDINES AS GLYCINE TRANSPORTER INHIBITORS GLAXO GROUP LIMITED (GB) 2007-11-28 EP disclosed
WO-2006094842-A1 ACYLATED PIPERIDIHES AS GLYCINE TRANSPORTER INHIBITORS GLAXO GROUP LIMITED (GB) 2006-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255144-A1 Acylated Piperidines as Glycine Transporter Inhibitors SLC1A1, SLC6A7, SLC1A2 SLC6A9 9/4885LMNA 4248/4885PTGS2 2558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.